- SteriMax acquired Andone Pharmaceuticals, expanding its presence beyond pharmaceuticals into the medical device and veterinary markets and strengthening its position among Canada’s largest privately owned pharmaceutical companies.
- The acquisition adds Andone’s pharmaceutical, medical device, and veterinary businesses, complementing SteriMax’s injectable portfolio and creating new growth opportunities in adjacent healthcare sectors.
- Andone founder Jay Barat will join SteriMax to lead its veterinary and medical device businesses, supporting the integration and future expansion of these segments.
- The combined company aims to leverage its broader product portfolio, expertise, and customer relationships to better serve healthcare providers across pharmaceutical, homecare, veterinary, and medical device markets in Canada.
Takeaways:
SteriMax’s acquisition of Andone broadens its growth runway beyond injectables into two adjacent, higher-diversification markets, medical devices and veterinary, so the main market implication is a stronger cross-sector platform with more end-customer reach and less dependence on pharmaceutical-only demand. Bringing Jay Barat in to run the new veterinary and device businesses also suggests SteriMax wants to preserve specialized commercial know-how while using its larger scale, which could make the combined company a more competitive private player in Canada across pharma, homecare, vet, and device channels.
Source: PRnewswire
